Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random

Hanjae Lee^{1

2}, Ohsang Kwon^{1

2

3

4}

Affiliations

¹ Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea.
² Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul, Republic of Korea.
³ Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
⁴ Institute of Human Environment Interface Biology, Seoul National University College of Medicine, Seoul, Republic of Korea.

Comment

Hanjae Lee et al. Br J Dermatol. 2022 Dec.

. 2022 Dec;187(6):840-841.

doi: 10.1111/bjd.21838. Epub 2022 Sep 2.

Hanjae Lee^{1

2}, Ohsang Kwon^{1

2

3

4}

¹ Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea.
² Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul, Republic of Korea.
³ Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
⁴ Institute of Human Environment Interface Biology, Seoul National University College of Medicine, Seoul, Republic of Korea.

No abstract available

Comment on

Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA, Apalla Z, Carrera C, Fattore D, Sollena P, Riganti J, Segura S, Freites-Martinez A, Lallas K, Romano MC, Oikonomou C, Starace M, Dimopoulos MA, Kyrgidis A, Lazaridou E, Giavedoni P, Annunziata MC, Peris K, Echeverría M, Lopez-Tujillo E, Syrigos K, Papageorgiou C, Podlipnik S, Fabbrocini G, Torre AC, Kemanetzi C, Villa-Crespo L, Lallas A, Stratigos AJ, Sibaud V. Nikolaou VA, et al. Br J Dermatol. 2022 Dec;187(6):962-969. doi: 10.1111/bjd.21781. Epub 2022 Sep 6. Br J Dermatol. 2022. PMID: 35861701

1. Wang LL, Patel G, Chiesa-Fuxench ZC et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol 2018; 154:1057-61.
1. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19:345-61.
1. Nikolaou V, Apalla Z, Carrera C et al. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentric study from the EADV-Task Force of Dermatology for Cancer Patients. Br J Dermatol 2022; 187:962-9.
1. Kwon CW, Land AS, Smoller BR et al. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor. J Eur Acad Dermatol Venereol 2017; 31:e349-50.
1. Apalla Z, Papageorgiou C, Lallas A et al. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept 2021; 11:e2021155.